title: Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.
abstract: Thirty years after its beginning, the HIV/AIDS epidemic is still raging around the world. According to UNAIDS, in 2011 alone 1.7M deaths were attributable to AIDS, and 2.5M people were newly infected by the virus. Despite the success in treating HIV-infected people with potent antiretroviral drugs, preventing HIV infection is the key to ending the epidemic. Recently, the efficacy of topical and systemic antiviral chemoprophylaxis (i.e., preexposure prophylaxis or "PrEP"), using the same drugs used for HIV treatment, has been demonstrated in a number of clinical trials. However, results from other trials have been inconsistent, especially those evaluating PrEP in women. These inconsistencies may result from our incomplete understanding of pharmacokinetics (PK)/pharmacodynamics (PD) at the mucosal sites of sexual transmission: the male and female gastrointestinal and reproductive tracts. The drug concentrations used in these trials were derived from those used for treatment; however, we still do not know the relationship between the therapeutic and the preventive dose. This article presents the first comprehensive review of the available data in the HIV pharmacology field from animal models to human studies, and outlines gaps, challenges, and future directions. Addressing these pharmacological gaps and challenges will be critical in selecting and advancing future PrEP candidates and strategies with the greatest impact on the HIV epidemic.
authors.affiliation: 1 NWJ Group , LLC, Wayne, Pennsylvania.
authors.forename: Joseph
authors.initials: J
authors.lastname: Romano
authors.forename: Angela
authors.initials: A
authors.lastname: Kashuba
authors.forename: Stephen
authors.initials: S
authors.lastname: Becker
authors.forename: James
authors.initials: J
authors.lastname: Cummins
authors.forename: Jim
authors.initials: J
authors.lastname: Turpin
authors.forename: Fulvia
authors.initials: F
authors.lastname: Veronese
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D018890:Chemoprevention / Q000379:methods*; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D041981:Gastrointestinal Tract / Q000737:chemistry; D005835:Genitalia / Q000737:chemistry; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D009092:Mucous Membrane / Q000737:chemistry
chemical_list: D019380:Anti-HIV Agents